Effective gene therapy with nonintegrating lentiviral vectors
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Retroviral and lentiviral vector integration into host-cell chromosomes carries with it a finite chance of causing insertional mutagenesis. This risk has been highlighted by the induction of malignancy in mouse models, and development of lymphoproliferative disease in three individuals with severe combined immunodeficiency-X1 (refs. 2,3). Therefore, a key challenge for clinical therapies based on retroviral vectors is to achieve stable transgene expression while minimizing insertional mutagenesis. Recent in vitro studies have shown that integration-deficient lentiviral vectors can mediate stable transduction. With similar vectors, we now show efficient and sustained transgene expression in vivo in rodent ocular and brain tissues. We also show substantial rescue of clinically relevant rodent models of retinal degeneration. Therefore, the high efficiency of gene transfer and expression mediated by lentiviruses can be harnessed in vivo without a requirement for vector integration. For therapeutic application to postmitotic tissues, this system substantially reduces the risk of insertional mutagenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NILVs encoding for in vivo expression of GFP have been reported in organs such as the brain, liver, and spinal cord via stable gene transfer for longer periods (up to months) in several studies [22,73,131,132,133,134].”
From Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through (2022) · cites this paper as [22]
In the citing paper
“A non-integrating LV was engineered to avoid unwanted integration. In these vectors, selected mutations were induced within the integrase coding region to eliminate the integrase activities without affecting reverse transcription and transport of the pre-integrating complex into the nucleus [48,49,50].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [49]
Citations
Cites
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903 · cited 1×
“Class I integration-deficient lentiviral vectors have been reported to be inefficient for transduction of dividing cells in vitro”
BackgroundLMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Self-citationA Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341 · cited 1×
“We produced paired integration-proficient and integration-deficient HIV-1 vectors using self-inactivating system”
MethodNaldini, L., Blömer, U., Gage, F. H., Trono, D., & Verma, I. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11382 · Cited by 1,499 · cited 1×
“In contrast, direct administration of nonintegrating vectors based on human immunodeficiency virus (HIV) or feline immunodeficiency virus (FIV) has not previously resulted in significant expression in vivo”
BackgroundA quantitative assay for HIV DNA integration in vivo
Butler, S. L., Hansen, M. S. T., & Bushman, F. D. (2001) · Nature Medicine · doi:10.1038/87979 · Cited by 687 · cited 1×
“We carried out qPCR titrations of total vector DNA according to a published protocol for late reverse transcriptase amplicon quantificatio”
MethodMurine leukemia induced by retroviral gene marking
Li, Z., Düllmann, J., Schiedlmeier, B., Schmidt, M., von Kalle, C., Meyer, J., Forster, M., Stocking, C., Wahlers, A., Frank, O., et al. (2002) · Science · doi:10.1126/science.1068893 · Cited by 525 · cited 1×
“We designed three different LAM-PCR reactions to scan vector regions downstream of the 5¢-dLTR (1), upstream of the 3¢-dLTR (2) and downstream of residual env sequences (a region including cPPT/CTS and internal promoter, 3) for integration junctions.”
MethodSelf-citationDemaison, C., Parsley, K., Brouns, G., Scherr, M., Battmer, K., Kinnon, C., Grez, M., & Thrasher, A. J. (2002) · Human Gene Therapy · doi:10.1089/10430340252898984 · Cited by 486
Self-citationSide effects of retroviral gene transfer into hematopoietic stem cells
Baum, C., Düllmann, J., Li, Z., Fehse, B., Meyer, J., Williams, D. A., & von Kalle, C. (2003) · Blood · doi:10.1182/blood-2002-07-2314 · Cited by 435
Case, S. S., Price, M. A., Jordan, C. T., Yu, X. J., Wang, L., Bauer, G., Haas, D. L., Xu, D., Stripecke, R., Naldini, L., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.2988 · Cited by 386
Shank, P. R., Hughes, S. H., Kung, H.-J., Majors, J. E., Quintrell, N., Guntaka, R. V., Bishop, J. M., & Varmus, H. E. (1978) · Cell · doi:10.1016/0092-8674(78)90063-6 · Cited by 383
Cited by
Items 201–300 of 459
Subramanian, G. (2004) · Kluwer Academic Publishers-Plenum Publishers eBooks · Cited by 28
Caruso, R. C., Aleman, T. S., Cideciyan, A. V., Roman, A. J., Sumaroka, A., Mullins, C. L., Boye, S. L., Hauswirth, W. W., & Jacobson, S. G. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-5559 · Cited by 26
Yang, G., Si-Tayeb, K., Corbineau, S., Vernet, R., Gayon, R., Dianat, N., Martinet, C., Clay, D., Goulinet-Mainot, S., Tachdjian, G., et al. (2013) · BMC Biology · doi:10.1186/1741-7007-11-86 · Cited by 26
“EF1α-GFP and APOA-II-GFP were produced in an integration-defective form, with a GAG/POL packaging plasmid encoding the D64V mutant integrase [14,15].”
Hu, B., Yang, H., Dai, B., Tai, A., & Wang, P. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.012 · Cited by 27
“The resulting NILVs could retain their ability to effectively transduce dividing and nondividing cells while providing long-term transgene expression in a variety of postmitotic tissues (Philippe et al. , 2006; Yanez-Munoz et al. , 2006; Apolonia et al. , 2007).”
InfluentialNew Methods for Disease Modeling Using Lentiviral Vectors
Alfranca, A., Campanero, M. R., & Redondo, J. M. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.08.001 · Cited by 28
CRISPR/Cas therapeutic strategies for autosomal dominant disorders
Caruso, S. M., Quinn, P. M. J., da Costa, B. L., & Tsang, S. H. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158287 · Cited by 29
Gene Therapy Regenerates Protein Expression in Cone Photoreceptors in Rpe65R91W/R91W Mice
Kostic, C., Crippa, S. V., Pignat, V., Bemelmans, A.-P., Samardzija, M., Grimm, C., Wenzel, A., & Arsenijevic, Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016588 · Cited by 26
“This effect is coherent with the improvement of scotopic ERG observed after gene transfer in adult Rpe65-deficient mice which are more severely affected than Rpe65 mice [9,11,13].”
ResultHuman gene therapy vectors derived from feline lentiviruses
Barraza, R., & Poeschla, E. M. (2008) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2008.01.009 · Cited by 31
“Indeed, this property has been utilized for retinal gene transfer with HIV-1 vectors (Yanez-Munoz et al., 2006).”
BackgroundSelden, C., Mellor, N., Rees, M., Laurson-Doube, J., Kirwan, M., Escors, D., Collins, M. K., & Hodgson, H. J. F. (2007) · The Journal of Gene Medicine · doi:10.1002/jgm.1000 · Cited by 30
“It remains to be seen whether the recent observations using non-integrating lentiviral vectors showing considerable promise in brain and retinal tissue of rodents for long term expression will be valid in man, and if so whether the efficiency may be further improved by growth factor addition [26].”
BackgroundThe second chance story of HIV-1 DNA: Unintegrated? Not a problem!
Wu, Y. (2008) · Retrovirology · doi:10.1186/1742-4690-5-61 · Cited by 31
Garoon, R. B., & Stout, J. T. (2016) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000256 · Cited by 25
Lee, M.-Y., Wang, H.-Z., White, T. W., Brooks, T., Pittman, A. M., Halai, H., Petrova, A., Xu, D., Hart, S. L., Kinsler, V. A., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.09.022 · Cited by 25
“were immortalized by transduction with a second-generation, replication-deficient, selfinactivating HIV-1 lentiviral vector (Yáñez-Muñoz et al., 2006) constructed with human papilloma virus type 16 E6/E7 cDNA (Supplementary Figure S3).”
Targeting vascular endothelial growth factor using retinal gene therapy
Chung, S. H., Frick, S. L., & Yiu, G. C. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4417 · Cited by 28
“To overcome this issue, inactivation at the 3' long terminal repeat (LTR) has been developed for selfinactivation vectors (64).”
BackgroundTannemaat, M. R., Boer, G. J., Verhaagen, J., & Malessy, M. J. A. (2007) · Neurosurgery · doi:10.1227/01.neu.0000306108.78044.a2 · Cited by 25
“LV vectors have previously been reported to give continuous transgene expression in vivo for months (14, 32).”
BackgroundResultZhavoronkov, A. A., Smit‐McBride, Z., Guinan, K. J., Litovchenko, M., & Moskalev, A. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0962-4 · Cited by 25
“The assortment of gene delivery vehicles for gene therapy products are expanding, and include lentivirals and adeno-associated viral vectors [108] in addition to nonviral gene delivery systems such as lipoplexes, polyplexes, inorganic nanoparticles, quantum dots, and protocells [109–111].”
BackgroundGene Therapy in Diabetic Retinopathy and Diabetic Macular Edema: An Update
Odio-Herrera, M., Loaiza, G. O., & Wu, L. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14093205 · Cited by 25
Targeted Gene Addition of Microdystrophin in Mice Skeletal Muscle via Human Myoblast Transplantation
Benabdallah, B., Duval, A., Rousseau, J., Chapdelaine, P., Holmes, M. C., Haddad, É., Tremblay, J. P., & Beausejour, C. M. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2012.55 · Cited by 26
Educational paper: Retinal dystrophies and gene therapy
Sundaram, V., Moore, A. T., Ali, R. R., & Bainbridge, J. W. (2011) · European Journal of Pediatrics · doi:10.1007/s00431-011-1615-2 · Cited by 30
“Lentiviral vectors integrate into the host genome, with theoretical potential for insertional mutagenesis [31], but non-integrating versions can also lead to efficient transduction [49].”
Self-citationCd, T., Smolenski, R. T., Harhun, M. I., Patel, H. S., Ahmed, S., Wanisch, K., Yáñez‐Muñoz, R. J., & Baines, D. L. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01993.x · Cited by 24
Self-citationThe promise of gene therapy for the treatment of epilepsy
Vezzani, A. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.12.1685 · Cited by 26
Lentiviral vectors in cancer immunotherapy
Lin, S., Wang, B., & Wang, L. (2008) · 国际外科学杂志 · doi:10.3760/cma.j.issn.1673-4203.2008.03.011 · Cited by 23
Targeted gene modification in mouse ES cells using integrase‐defective lentiviral vectors
Okada, Y., Ueshin, Y., Hasuwa, H., Takumi, K., Okabe, M., & Ikawa, M. (2009) · genesis · doi:10.1002/dvg.20469 · Cited by 23
Experimental gene transfer to the corneal endothelium
Kampik, D., Ali, R. R., & Larkin, F. (2011) · Experimental Eye Research · doi:10.1016/j.exer.2011.07.001 · Cited by 26
Self-citationHutson, T. H., Foster, E., Dawes, J. M., Hindges, R., Yáñez‐Muñoz, R. J., & Moon, L. D. F. (2012) · The Journal of Gene Medicine · doi:10.1002/jgm.2626 · Cited by 24
“The lentiviral titre was determined by serial dilution and transduction of HeLa cells followed by flow cytometry as described previously [21].”
BackgroundMethodInfluentialSelf-citationLu‐Nguyen, N., Broadstock, M., Schliesser, M. G., Bartholomae, C. C., Kalle, C. V., Schmidt, M., & Yáñez‐Muñoz, R. J. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.003 · Cited by 25
Self-citationRecombinant lentivector as a genetic immunization vehicle for antitumor immunity
He, Y., Munn, D. H., & Falo, L. D. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.6.913 · Cited by 24
Lentiviral vectors for gene transfer into the spinal cord glial cells
Meunier, A., & Pohl, M. (2009) · Gene Therapy · doi:10.1038/gt.2009.22 · Cited by 23
Simian immunodeficiency virus-Vpx for improving integrase defective lentiviral vector-based vaccines
Negri, D. R. M., Rossi, A., Blasi, M., Michelini, Z., Leone, P., Chiantore, M. V., Baroncelli, S., Perretta, G., Cimarelli, A., Klotman, M. E., et al. (2012) · Retrovirology · doi:10.1186/1742-4690-9-69 · Cited by 23
“both immunization and gene therapy purposes has been reported by several groups [1-11].”
BackgroundState-of-the-art gene therapy in epilepsy
Walker, M. C. (2025) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001349 · Cited by 23
CRISPR Technology for Ocular Angiogenesis
Chung, S. H., Sin, T.-N., Ngo, T., & Yiu, G. C. (2020) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.594984 · Cited by 21
From microsurgery to nanosurgery: how viral vectors may help repair the peripheral nerve
Tannemaat, M. R., Boer, G. J., Eggers, R., Malessy, M. J. A., & Verhaagen, J. (2009) · Progress in brain research · doi:10.1016/s0079-6123(09)17512-x · Cited by 25
Daenthanasanmak, A., Salguero, G., Borchers, S., Figueiredo, C., Jacobs, R., Sundarasetty, B. S., Schneider, A., Schambach, A., Eiz‐Vesper, B., Blasczyk, R., et al. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.05.063 · Cited by 21
Current trends in gene therapy for retinal diseases (Review)
Moraru, A. D., Costin, D., Iorga, R. E., Munteanu, M., Moraru, R., & Brănişteanu, D. C. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10948 · Cited by 25
“Over the past two decades, major improvements in surgical techniques necessary for the delivery of modified genes to the retinal tissue have been achieved, thus contributing to the development of novel and revolutionary therapeutic strategies (1,2).”
BackgroundInfluentialMatet, A., Kostic, C., Bemelmans, A.-P., Moulin, A., Rosolen, S. G., Martin, S., Mavilio, F., Amirjanians, V., Stieger, K., Lorenz, B., et al. (2017) · Translational Research · doi:10.1016/j.trsl.2017.06.012 · Cited by 20
Xu, Z., Chen, F., Zhang, L., Lu, J., Xu, P., Liu, G., Xie, X., Mu, W., Wang, Y., & Liu, D. (2016) · Science China Life Sciences · doi:10.1007/s11427-016-0067-0 · Cited by 20
“Therefore, NIL vectors have been demonstrated to be an efficient and safe gene delivery system (Kohn et al., 2003), and they are useful in gene therapy applications (Yáñez-Muñoz et al., 2006).”
MethodWang, X., Zhuang, W., Fu, W., Wang, X., Lv, E., Li, F., Zhou, S., Rausch, W., & Wang, X. (2018) · Europe PMC (PubMed Central) · Cited by 23
Pleiotropic Nature of HIV‐1 Integrase Mutations
Engelman, A. (2011) · HIV‐1 Integrase · doi:10.1002/9781118015377.ch6 · Cited by 20
Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance
Richetta, C., Tu, N. Q., & Delelis, O. (2022) · Viruses · doi:10.3390/v14122591 · Cited by 24
Rivière, J., Hauer, J., Poirot, L., Brochet, J., Souque, P., Mollier, K., Gouble, A., Charneau, P., Fischer, A., Pâques, F., et al. (2014) · Gene Therapy · doi:10.1038/gt.2014.20 · Cited by 20
Immune modulation by genetic modification of dendritic cells with lentiviral vectors
Liechtenstein, T., Pérez‐Janices, N., Bricogne, C., Lanna, A., Dufait, I., Goyvaerts, C., Laranga, R., Padella, A., Vargas, F. A., Baratchian, M., et al. (2013) · Virus Research · doi:10.1016/j.virusres.2013.05.007 · Cited by 24
Serguera, C., & Bemelmans, A. (2014) · Revue Neurologique · doi:10.1016/j.neurol.2014.09.004 · Cited by 22
Ahmed, S., Waddington, S. N., Boza-Moran, M.-G., & Yáñez‐Muñoz, R. J. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.12.029 · Cited by 20
Self-citationYoung, J., Tang, Z., Yu, Q., Yu, D., & Wu, Y. (2008) · Retrovirology · doi:10.1186/1742-4690-5-36 · Cited by 19
“non-dividing cells, such as ocular or neuronal cells, for gene therapy [60-62].”
BackgroundIntegrase deficient lentiviral vector: prospects for safe clinical applications
Yew, C.-H. T., Gurumoorthy, N., Nordin, F., Tye, G. J., Zaman, W. S. W. K., Tan, J. J., & Ng, M. H. (2022) · PeerJ · doi:10.7717/peerj.13704 · Cited by 21
Vector design for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells
Schambach, A., & Baum, C. (2007) · DNA repair · doi:10.1016/j.dnarep.2007.03.017 · Cited by 21
“To advance this technology, lentiviral delivery of episomal DNA [118,119] and the incorporation of scaffold attachment region to improve episome retention represent promising developments [120-122].”
BackgroundDu, J., Zeng, J., Zhao, Y. H., Boulaire, J., & Wang, S. (2009) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2009.06.017 · Cited by 18
Antiangiogenic Eye Gene Therapy
Corydon, T. J. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.064 · Cited by 21
“Another important challenge is to reduce the risk of genotoxicity, and different approaches using more efficient vectors to avoid multiple integrations in a single cell, or expression cassettes that avoid long-distance enhancer interactions or incorporate insulator sequences, as well as optimized IDLVs, have been sugge…”
InfluentialRecent Advancements in Gene Therapy for Hereditary Retinal Dystrophies
Öner, A. (2017) · Turkish Journal of Ophthalmology · doi:10.4274/tjo.41017 · Cited by 22
siRNA and shRNA as Anticancer Agents in a Cervical Cancer Model
Gu, W., Tom, L. N., & McMillan, N. A. J. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-191-8_12 · Cited by 21
In vivo targeting of subventricular zone astrocytes
Mamber, C., Verhaagen, J., & Hol, E. M. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.04.007 · Cited by 23
Targeting Lentiviral Vectors for Cancer Immunotherapy
Vargas, F. A., Breckpot, K., Collins, M. K., & Escors, D. (2011) · Current Cancer Therapy Reviews · doi:10.2174/157339411797642605 · Cited by 19
Non-Integrative Lentivirus Drives High-Frequency cre-Mediated Cassette Exchange in Human Cells
Torres-Ruiz, R., García, A., Payá, M., & Ramírez, J. C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019794 · Cited by 18
“Importantly, frequencies of RMCE are two log units above the very low frequency of integration of the IDLV, estimated between 1610(24) to 2610(25) integrants/viral genome copies [36,37], which renders its selection during the procedure negligible, given frequencies of RMCE close to 1% of the transduced cells at low MO…”
BackgroundNonintegrating Foamy Virus Vectors
Deyle, D. R., Li, Y., Olson, E. M., & Russell, D. W. (2010) · Journal of Virology · doi:10.1128/jvi.00394-10 · Cited by 21
“The D100V mutation is similar to the D64V mutation used previously in NILV vectors (1, 39, 41, 60), and the D157A mutation has been shown to produce integrase-deficient FV vectors (9, 12).”
MethodA Single Intravenous AAV9 Injection Mediates Bilateral Gene Transfer to the Adult Mouse Retina
Bemelmans, A., Duqué, S. I., Rivière, C., Astord, S., Desrosiers, M., Marais, T., Sahel, J., Voït, T., & Barkats, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061618 · Cited by 22
Hamilton, A. M., Foster, P. J., & Ronald, J. A. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.111 · Cited by 17
Mucopolysaccharidoses type I gene therapy
Hurt, S. C., Dickson, P., & Curiel, D. T. (2021) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12414 · Cited by 16
Li, A., Ji, B., Yang, Y., Ye, B., Zhu, Q., Hu, X., Liu, Y., Zhou, P., Liu, J., Gao, R., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1164448 · Cited by 18
Fischer, A., Ehrlich, A., Plotkin, Y., Ouyang, Y., Asulin, K., Konstantinos, I., Fan, C., Nahmias, Y., & Willner, I. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202311590 · Cited by 17
Retinal gene therapy: current progress and future prospects
Ku, C. A., & Pennesi, M. E. (2015) · Expert Review of Ophthalmology · doi:10.1586/17469899.2015.1035711 · Cited by 18
“Recent developments in integration-deficient vectors, however, may address concerns of insertional mutagenesis [93].”
BackgroundRetroviral integration profiles: their determinants and implications for gene therapy
Lim, K. (2012) · BMB Reports · doi:10.5483/bmbrep.2012.45.4.207 · Cited by 17
“Alternatively, integration-defective retroviruses have been generated via site-specific mutagenesis of integrase to develop safer vector systems (47, 48).”
MethodDesigning Lentiviral Gene Vectors
Tolmachov, O. E., Tolmachova, T., & Al-Allaf, F. A. (2011) · InTech eBooks · doi:10.5772/17361 · Cited by 22
Kampik, D., Basche, M., Luhmann, U. F. O., Nishiguchi, K. M., Williams, J. A. E., Greenwood, J., Moss, S. E., Han, H. R., Azam, S. A., Durán, Y., et al. (2017) · Gene Therapy · doi:10.1038/gt.2017.89 · Cited by 16
Self-citationQasim, W., Vink, C. A., & Thrasher, A. J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.76 · Cited by 19
Self-citationNew Tools for Epilepsy Therapy
Falcicchia, C., Simonato, M., & Verlengia, G. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00147 · Cited by 18
“To overcome this problem, a new class of lentiviruses has been generated to confer a steady expression of the transgene after in vivo infection in neurons in vivo without integration (Yáñez-Muñoz et al., 2006).”
BackgroundGrandchamp, N., Henriot, D., Philippe, S., Amar, L., Ursulet, S., Serguera, C., Mallet, J. J., & Sarkis, C. (2011) · Genetic Vaccines and Therapy · doi:10.1186/1479-0556-9-1 · Cited by 19
“They have great potential for clinical use, particularly in non-dividing cells where their episomal genome remains stable for at least one year [32].”
BackgroundViral and non-viral gene delivery and its role in pluripotent stem cell engineering
Kane, N. M., McRae, S., Denning, C. N., & Baker, A. H. (2008) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2008.10.002 · Cited by 15
Republished review: Gene therapy for ocular diseases
Liu, M. M., Tuo, J., & Chan, C. (2011) · Postgraduate Medical Journal · doi:10.1136/pgmj.2009.174912rep · Cited by 18
Wang, H., Cao, H., Wohlfahrt, M. E., Kiem, H., & Lieber, A. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.01.014 · Cited by 15
“Nonintegrating lentivirus vector have shown promise for transient expression of transgenes in HSC but suffer from relatively low transduction and expression levels [3].”
BackgroundIntegrase Defective, Nonintegrating Lentiviral Vectors
Michelini, Z., Negri, D. R. M., & Cara, A. (2009) · Methods in molecular biology · doi:10.1007/978-1-60761-533-0_6 · Cited by 18
Hu, P., Li, Y., Sands, M. S., McCown, T. J., & Kafri, T. (2015) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.25 · Cited by 15
Ex vivo expansion of hematopoietic stem cells and gene therapy development
Zubler, R. H. (2006) · Swiss Medical Weekly · doi:10.4414/smw.2006.11424 · Cited by 15
“However, transgene expression in such post-mitotic cells has also recently been obtained with a non-integrating lentivector [ 22 ].”
BackgroundLentiviral Vectors: From Wild-Type Viruses to Efficient Multi-Functional Delivery Vectors
Arrasate, A., Lopez-Robles, C., Zuazo, M., Baños-Mateos, S., Martín, C., Lamsfus‐Calle, A., & Fertin, M. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178497 · Cited by 15
Intraocular mRNA delivery with endogenous MmPEG10-based virus-like particles
Li, M., Liu, Z., Wang, D., Ye, J., Shi, Z., Pan, C., Zhang, Q., Ju, R., Zheng, Y., & Liu, Y. (2024) · Experimental Eye Research · doi:10.1016/j.exer.2024.109899 · Cited by 16
Carbon quantum dots for the diagnosis and treatment of ophthalmic diseases
Zhang, X., Yang, L. Y., Wang, F., & Su, Y. (2024) · Human Cell · doi:10.1007/s13577-024-01111-9 · Cited by 15
Low dose ionizing radiation strongly stimulates insertional mutagenesis in a γH2AX dependent manner
Zelensky, A. N., Schoonakker, M., Brandsma, I., Tijsterman, M., van Gent, D. C., Essers, J., & Kanaar, R. (2020) · PLoS Genetics · doi:10.1371/journal.pgen.1008550 · Cited by 15
“We also observed 11 S-RI [Fig 1E] with integrase-deficient HIV-1 lentiviral (IDLV) vectors [27,28] whose RNA genomes are 12 reverse-transcribed normally, but accumulate as circular or linear episomal DNA because of the 13 inactivating D64V mutation in the integrase [29].”
Gabriel, R., Kutschera, I., Bartholomae, C. C., Kalle, C. V., & Schmidt, M. (2014) · Journal of Visualized Experiments · doi:10.3791/51543 · Cited by 21
Self-citationBalaggan, K. S., Durán, Y., Georgiadis, A., Thaung, C., Barker, S. E., Buch, P. K., MacNeil, A., Robbie, S. J., Bainbridge, J. W., Smith, A. J., et al. (2011) · Gene Therapy · doi:10.1038/gt.2011.194 · Cited by 18
Self-citationIrwan, I. D., & Cullen, B. R. (2021) · Journal of Virology · doi:10.1128/jvi.00285-21 · Cited by 15
Bockstael, O., Melas, C., Pythoud, C., Levivier, M., McCarty, D. M., Samulski, R. J., Witte, O. D., & Tenenbaum, L. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.216 · Cited by 15
“However, for therapeutic gene delivery, the use of a nonintegrative vector would be preferred in order to minimize the risk of insertional mutagenesis in dividing cells (Yanez-Munoz et al., 2006).”
Saeed, M. Q., Dufour, N., Bartholmae, C., Sieranska, U., Knopf, M., Thierry, E., Thierry, S., Delelis, O., Grandchamp, N., Pilet, H., et al. (2014) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2014.65 · Cited by 16
Self-citationRossi, A., Michelini, Z., Leone, P., Borghi, M., Blasi, M., Bona, R., Spada, M., Grasso, F., Gugliotta, A., Klotman, M. E., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107377 · Cited by 16
“This is in agreement with reports showing that IDLV persists up to 9 months from the inoculum in non-dividing cells or tissues [45–49].”
ResultInduction of T cell immunity by cutaneous genetic immunization with recombinant lentivector
He, Y., & Falo, L. D. (2006) · Immunologic Research · doi:10.1385/ir:36:1:101 · Cited by 14
“level gene expression in non-dividing cells (39).”
Steinrigl, A., Nosek, D., Ertl, R., Günzburg, W. H., Salmons, B., & Klein, D. (2007) · Virology · doi:10.1016/j.virol.2006.11.037 · Cited by 13
“However, very recent publications show that even EGFP expression from IN-deficient HIV-1 vectors can be surprisingly high (Nightingale et al., 2006; Yanez-Munoz et al., 2006).”
BackgroundPrime Editing: The Next Frontier in Precision Gene Therapy
Aliciaslan, M., Erbasan, E., Erendor, F., & Şanlıoğlu, S. (2025) · The Journal of Gene Medicine · doi:10.1002/jgm.70040 · Cited by 17
Multiple imputation and direct estimation for qPCR data with non-detects
Sherina, V., McMurray, H. R., Powers, W., Land, H., Love, T., & McCall, M. N. (2020) · BMC Bioinformatics · doi:10.1186/s12859-020-03807-9 · Cited by 15
Introduction to Viral Vectors and Other Delivery Methods for Gene Therapy of the Nervous System
Manfredsson, F. P. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3271-9_1 · Cited by 17
Jugular Vein Injection of High-Titer Lentiviral Vectors Does Not Transduce the Aorta—Brief Report
Bi, L., Wacker, B. K., Stamatikos, A., Sethuraman, M., Komandur, K., & Dichek, D. A. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315125 · Cited by 13
“18 If there were abundant episomal LV-GFP DNA in the aorta, our assay would have detected it.”
Driving DNA transposition by lentiviral protein transduction
Cai, Y., & Mikkelsen, J. G. (2014) · Mobile Genetic Elements · doi:10.4161/mge.29591 · Cited by 14
Jia, J., Hao, Y., Zhang, P., Cao, X., An, L., Wang, H., Ma, Q., Jin, X., & Ma, X. (2025) · European journal of medical research · doi:10.1186/s40001-025-02499-2 · Cited by 13
“However, linear amplification-mediated PCR (LAM-PCR) revealed low-frequency host DNA integration events associated with IDLV [44].”
In vivo delivery systems for CRISPR genome editing: Viral and non-viral carriers
Lee, Y., Kim, B., Lee, D., Cheon, S. Y., Lim, S. G., Kim, Y., & Koo, H. (2025) · Applied Physics Reviews · doi:10.1063/5.0228874 · Cited by 13
Development and Challenges of Nanovectors in Gene Therapy
Liu, Y., Rohrs, J. A., & Wang, P. (2014) · Nano LIFE · doi:10.1142/s1793984414410074 · Cited by 13
Novel gene therapeutic strategies for the induction of tolerance in cornea transplantation
Ritter, T., & Pleyer, U. (2009) · Expert Review of Clinical Immunology · doi:10.1586/eci.09.59 · Cited by 13
Yan, Q., Zhu, H., Wang, F., Feng, J.-Y., Wang, W., Shi, X., Zhou, Y., Zhang, X., & Sun, X. (2015) · Current Eye Research · doi:10.3109/02713683.2015.1006371 · Cited by 12
“Lentiviruses are enveloped retroviruses which have the ability of infecting non-dividing cells and offer well-performed transduction in rodent ocular and brain tissues.(29,30)”
BackgroundNovel approaches to in vitro transgenesis
Adamson, A. D., Jackson, D. A., & Davis, J. R. (2010) · Journal of Endocrinology · doi:10.1677/joe-10-0417 · Cited by 20
Safe and neuroprotective vectors for long-term traumatic brain injury gene therapy
Blanco‐Ocampo, D., Cawen, F. A., Álamo-Pindado, L. A., Negro‐Demontel, M. L., & Peluffo, H. (2019) · Gene Therapy · doi:10.1038/s41434-019-0073-8 · Cited by 12
Grandchamp, N., Altémir, D., Philippe, S., Ursulet, S., Pilet, H., Serre, M.-C., Lenain, A., Serguera, C., Mallet, J., & Sarkis, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099649 · Cited by 11
Retrovirus-based vectors for transient and permanent cell modification
Schott, J. W., Hoffmann, D., & Schambach, A. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.09.004 · Cited by 13
Bona, R., Michelini, Z., Mazzei, C., Gallinaro, A., Canitano, A., Borghi, M., Vescio, M. F., Virgilio, A. D., Pirillo, M. F., Klotman, M. E., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.09.011 · Cited by 12
Nguyen, T. H., & Ferry, N. (2007) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.1.1.155 · Cited by 13
Abe, T., Wakusawa, R., Seto, H., Asai, N., Saito, T., & Nishida, K. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-0947 · Cited by 13
Metadata
- Authors
- Yáñez-Muñoz, R. J., Balaggan, K. S., MacNeil, A., Howe, S. J., Schmidt, M., Smith, A. J., Buch, P., MacLaren, R. E., Anderson, P. N., Barker, S. E., Duran, Y., Bartholomae, C., von Kalle, C., Heckenlively, J. R., Kinnon, C., Ali, R. R., & Thrasher, A. J.
- Affiliations
- University College London (GB)
- University of Freiburg (DE)
- Great Ormond Street Hospital (GB)
- Corresponding author
- Ali, Robin R
- ORCID
- Venue
- Nature Medicine
- Published
- 2006-02-19
- Volume
- 12
- Issue
- 3
- Pages
- 348-353
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2167845957
- Cited by
- 460
- References
- 30
- Citations by year
- 2026: 4 · 2025: 18 · 2024: 8 · 2023: 10 · 2022: 14 · 2021: 14 · 2020: 13 · 2019: 19 · 2018: 11 · 2017: 21 · 2016: 19 · 2015: 24 · 2014: 31 · 2013: 27 · 2012: 35
- FWCI
- 21.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Wellcome Trust
- University College London
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- insertional mutagenesis, retroviral vectors, stable transgene expression, ocular gene therapy, retinal degeneration, postmitotic tissues
- MeSH terms
- Retinoid Isomerohydrolase, Animals, Brain, Carrier Proteins, Electroretinography, Eye Proteins, Female, Genetic Vectors, HeLa Cells, Humans, Pigment Epithelium of Eye, Retina, Tumor Cells, Cultured, Genetic Therapy, Lentivirus, Virus Integration, cis-trans-Isomerases, Green Fluorescent Proteins, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.